Shares of Recro Pharma Inc (NASDAQ:REPH) have been given an average recommendation of “Buy” by the eight research firms that are presently covering the company, MarketBeat.com reports. Three research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $14.13.
REPH has been the subject of several research reports. UBS initiated coverage on Recro Pharma in a research note on Tuesday, February 13th. They set an “outperform” rating for the company. Oppenheimer set a $19.00 price objective on Recro Pharma and gave the stock a “buy” rating in a research note on Wednesday, February 28th. CIBC initiated coverage on Recro Pharma in a research note on Wednesday, February 14th. They set an “outperform” rating and a $19.00 price objective for the company. ValuEngine raised Recro Pharma from a “sell” rating to a “hold” rating in a research note on Thursday, March 1st. Finally, Zacks Investment Research raised Recro Pharma from a “sell” rating to a “hold” rating in a research note on Wednesday, March 21st.
REPH opened at $10.19 on Wednesday. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.55 and a current ratio of 1.75. Recro Pharma has a fifty-two week low of $5.81 and a fifty-two week high of $12.23.
Recro Pharma (NASDAQ:REPH) last released its quarterly earnings data on Tuesday, February 27th. The specialty pharmaceutical company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($0.85) by $0.22. The business had revenue of $19.04 million during the quarter, compared to analyst estimates of $12.88 million. Recro Pharma had a negative return on equity of 75.97% and a negative net margin of 69.61%. analysts forecast that Recro Pharma will post -3.02 EPS for the current fiscal year.
In other news, major shareholder Healthcare Master Fun Broadfin sold 200,000 shares of the firm’s stock in a transaction on Tuesday, March 13th. The stock was sold at an average price of $10.07, for a total value of $2,014,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 21.60% of the company’s stock.
Several institutional investors have recently modified their holdings of the company. BlackRock Inc. boosted its position in shares of Recro Pharma by 1.4% in the fourth quarter. BlackRock Inc. now owns 1,011,855 shares of the specialty pharmaceutical company’s stock worth $9,359,000 after buying an additional 13,799 shares during the period. Alyeska Investment Group L.P. boosted its position in shares of Recro Pharma by 3.4% in the third quarter. Alyeska Investment Group L.P. now owns 906,398 shares of the specialty pharmaceutical company’s stock worth $8,139,000 after buying an additional 29,799 shares during the period. Lyon Street Capital LLC acquired a new stake in shares of Recro Pharma in the fourth quarter worth $3,362,000. Cadence Capital Management LLC boosted its position in shares of Recro Pharma by 7.8% in the fourth quarter. Cadence Capital Management LLC now owns 180,715 shares of the specialty pharmaceutical company’s stock worth $1,672,000 after buying an additional 13,078 shares during the period. Finally, Northern Trust Corp boosted its position in shares of Recro Pharma by 428.5% in the second quarter. Northern Trust Corp now owns 178,437 shares of the specialty pharmaceutical company’s stock worth $1,254,000 after buying an additional 144,676 shares during the period. 57.85% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “Recro Pharma Inc (REPH) Receives $14.13 Average PT from Brokerages” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another site, it was illegally stolen and reposted in violation of international copyright legislation. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/07/recro-pharma-inc-reph-receives-14-13-average-pt-from-brokerages.html.
About Recro Pharma
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.